# US 2024/0390470 A1 · Non-Toxin Antigens For Clostridioides Difficile Vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390470 A1
- Document ID: US20240390470A1
- Status: Published application
- Kind: A1
- Application number: 18/671,007
- Filed: 2024-05-22
- Published: 2024-11-28
- Earliest claimed: 2023-05-22
- Assignees: Vanderbilt University; The United States Government as represented by the Department of Veterans Affairs
- Applicants: Vanderbilt University; The United States Government As Represented by the Department of Veterans Affairs
- Inventors: D. Borden LACY; Audrey THOMAS
- Web page: https://patentgrep.com/patent/US20240390470A1

## CPC

- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61K 31/4164: 1,3-Diazoles
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61P 31/04: Antibacterial agents
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/575: {humoral response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are C. difficile surface proteins that can serve as antigens in a vaccine to prevent C. difficile infection. While many trials have been focused on the use of the C. difficile toxins as antigens, the neutralization of toxins does not prevent colonization by the organism.

## Claims

### Claim 1

A vaccine composition comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 C. difficile proteins (or immunogenic fragments thereof) selected from the group consisting of polysaccharide deacetylase, glucosaminidase domain-cont. protein, N-acetylmuramoyl-L-alanine amidase, C40 peptidase 1, C40 peptidase 2, FIgK (flagellar hook-associated protein), FlgD (flagellar basal body mod. protein), FIgG (flagellar basal body rod), FIgE (flagellar hook-basal body protein), DUF3794 domain-containing protein, S8 peptidase, N-acetylglucosaminidase, FliD (flagellar cap protein), NlpC/P60-family protein, Cell wall protein 12, and Cell wall protein 21, in a pharmaceutically acceptable carrier or excipient.

### Claim 2 (depends on 1)

The vaccine composition of claim 1, comprising a combination of FIgG, FIgE, and FIgK proteins in a ternary complex.

### Claim 3 (depends on 1)

The vaccine composition of claim 1, further comprising recombinantly-produced C. difficile toxins TcdA, TcdB, and/or CDT.

### Claim 4 (depends on 1)

The vaccine composition of claim 1, further comprising an adjuvant.

### Claim 5 (depends on 1)

The vaccine composition of claim 1, further comprising toxin antigens and an adjuvant.

### Claim 6 (depends on 1)

The vaccine of claim 1, wherein the C. difficile proteins (or immunogenic fragments thereof) are in a cell-free preparation.

### Claim 7 (depends on 1)

The vaccine of claim 1, wherein the C. difficile proteins (or immunogenic fragments thereof) are recombinant polypeptides.

### Claim 8 (depends on 1)

A method for preventing, treating, or suppressing Clostridioides difficile infection in a subject, said method comprising administering to the subject a therapeutically effective amount of the vaccine composition of claim 1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the vaccine composition is administered intrarectally, orally or by enema, intravenously, subcutaneously, intramuscularly or transdermally.

### Claim 10 (depends on 8)

The method of claim 8, further comprising administering to the subject a second agent.

### Claim 11 (depends on 10)

The method of claim 10, wherein the second agent is an antibiotic.

### Claim 12 (depends on 11)

The method of claim 11, wherein the antibiotic is vancomycin, metronidazole, or fidaxomicin.
